TABLE: Avalanche outperforms with the week's best IPO
This article was originally published in Scrip
Executive Summary
Gene therapy for eye diseases captured the interest of investors during the week ending 1 August with an initial public offering from Avalanche Biotechnologies that launched at the top of a preliminary price range and a first-day closing price that was 47% above the IPO value.
You may also be interested in...
Case Studies: How Three Public Companies Financed R&D In A Tough Market
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
Need a specific report? 1000+ reports available
Buy Reports